Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia.

摘要

There are several papers to show that enhanced intestinal cholesterol absorption is associated with the increased risk for CAI| [8,9]. Framingham Offspring Study revealed that decrease of lathosterof: and increase of sitosterol levels, which reflected lower cholesterol synthesis and higher intestinal diolesterol absorption, respectively, were independent predictors of prevalent cardiovascular disease in patients with CAD [8]. Since oxidized cholesterol in the diet is absorbed by the small intestine and incorporated not only into chylomicrons, but also into endogenous LDL [10], circulating level of oxidized LDLs could be influenced by quantity of cholesterol absorption into the intestine. These findings led us to speculate that ezetimibe, a specific inhibitor of intestinal cholesterol absorption and widely used drug for the treatment of hypercholesterolemia [10,11], may decrease circulating level of oxidized LDLs. In this study, we examined whether ezetimibe treatment could decrease serum level of MDA-LDL in patients with hypercholesterolemia.